Adult Obesity — Pharmacological Interventions
Publication Date: October 20, 2022
Key Points
Key Points
- The prevalence of obesity in the United States has increased dramatically over the past few decades from 30.5% in 1999–2000 to 41.9% in 2019–2020.
- In adults, obesity-related complications such as cardiovascular disease, stroke, type 2 diabetes mellitus (T2DM), nonalcoholic steatohepatitis, obstructive sleep apnea, osteoarthritis, and certain types of cancer (e.g., colorectal cancer) have also increased, contributing to high morbidity and mortality.
- Lifestyle intervention(s) has limited effectiveness and durability for most individuals.
- Pharmacological therapies with high efficacy in achieving weight loss have seen limited use, partly due to lack of familiarity and limited insurance coverage.
- A small number of providers are responsible for >90% of the anti-obesity medication prescriptions.
Treatment
Treatme...
...th obesity or overweight with weight-related com...
...adults with obesity or overweight with weight-re...
...lts with obesity or overweight with weight-rela...
...with obesity or overweight with weight-related c...
...ts with obesity or overweight with weight-related...
...In adults with obesity or overweight w...
...lts with obesity or overweight with weig...
...with obesity or overweight with weight...
...lts with body mass index (BMI) betwee...
...e 1. Anti-obesity MedicationsHaving troubl...
...Pharmacological Interventions for Adults...